Navigation Links
Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
Date:10/25/2011

ses caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
4. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
5. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
6. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
7. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
8. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
9. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  China Cord Blood Corporation (NYSE: CO ... financial results for the first quarter of fiscal year ... in the US.  The Company will ... Friday, August 29, 2014 to discuss its financial performance ... developments, followed by a question and answer session.  Interested ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Hospitals in Western Pennsylvania Earn Designation, PITTSBURGH, ... named Allegheny General Hospital, UPMC Presbyterian Shadyside and ... Rare Cancers., Complex and rare cancers comprise ... making it difficult for patients to locate or,research ...
... has announced,development of a chemically synthesized vaccine specific ... patented Replikins(TM) technology.,When the vaccine was administered orally ... Taura virus. The specificity of the protective,effect was ... active,regions in the vaccine, and as a result ...
... Prescribing of Copaxone over an Interferon-Beta Therapy, According to a ... ... Resources, WALTHAM, Mass., March 11 Decision Resources, one ... issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient share among ...
Cached Biology Technology:Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
(Date:8/20/2014)... fires are visible in in this image of the ... of these were most likely intentionally set in order ... a forest or stand of trees where the land ... deforestation include conversion of forestland to farms, ranches, or ... dark green of the Amazon Rainforest in the middle ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Ind. - Face-to-face workplace interactions may be the best ... organ donors, according to new research from Purdue University. ... learn about health and wellness issues, but how information ... for sensitive health topics such as organ donation," said ...
... Boston University biology professor Richard Primack, graduate student ... analysis of the changing arrival dates of migratory birds ... Thoreau from the 1850,s. This research builds on earlier ... Concord respond rapidly to temperature and are now flowering ...
... Coulter, Ph.D., a neuroscientist at The Children,s Hospital ... Award for Basic Science from the American Epilepsy ... to epilepsy research on Monday, Dec. 6 at ... the most prestigious prizes for research in epilepsy, ...
Cached Biology News:Study: Personal contacts at work help people better understand organ donation 2Study: Personal contacts at work help people better understand organ donation 3Epilepsy researcher at the Children's Hospital of Philadelphia receives scientific prize 2
EnzChek cellulase substrate *blue fluorescent, 339/452...
... 0.5-10 Kb RNA Ladder is suitable for sizing single-stranded ... glyoxal or formaldehyde agarose gels. The ladder consists of ... 3 4 6 8 and 10 kb) to simplify ... than the other bands allowing easy orientation and identification ...
...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Biology Products: